BioSenic S.A. (BIOS.BR)
Chart Events
Performance Outlook
| Previous Close | 0.1370 |
| Open | 0.1252 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1252 - 0.1364 |
| 52 Week Range | 0.0862 - 0.5280 |
| Volume | |
| Avg. Volume | 299,313 |
| Market Cap | 16.915M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4000 |
| Earnings Date | May 23, 2023 - May 29, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BIOS.BR
Related Research
- GlobeNewswire
BioSenic provides Financial Update and Financial Calendar 2023
INSIDE INFORMATION Mont-Saint-Guibert, Belgium, March 31, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, provides today a financial update and publishes its financial calendar for the year 2023. Financial Update As a result of cost management efforts made and payments received (mainly from Pregene) in Q1 2023, BioSenic Group now anticipates having sufficient cash to carry out it
- GlobeNewswire
BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
INSIDE INFORMATION Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy Mont-Saint-Guibert, Belgium, March 30, 2023, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, today announces that data providing additional details about the mechanism of action of its lead API arsenic trioxide (ATO) to pr
- GlobeNewswire
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
REGULATED INFORMATION New analysis and formal identification of patient subsets open up further potential clinical development options for JTA-004 Mont-Saint-Guibert, Belgium, March 16, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, announces today it has re-evaluated the results of its Phase III trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). B
